GlassScriptPhysician profile
Lauren E Meyer
NPI 1942889563
$5,293.22
in general payments reported to CMS, 2019-2025
41 companies · $669 in 2025
The $669 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,101 · 2023: $2,035 · 2024: $1,489 · 2025: $669.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,192.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $829.22 | 2022-2025 | Dupixent, Evkeeza |
| Astrazeneca Pharmaceuticals LP | $816.06 | 2022-2025 | Tezspire, Airsupra, Breztri |
| Genzyme Corporation | $626.29 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $353.54 | 2022-2024 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Abbvie INC. | $335.58 | 2022-2025 | |
| Actelion Pharmaceuticals US, INC. | $305.96 | 2022-2025 | Opsumit, Uptravi |
| United Therapeutics Corporation | $293.72 | 2022-2025 | |
| Jazz Pharmaceuticals INC. | $207.46 | 2022-2025 | |
| Lilly USA, LLC | $192.12 | 2023-2025 | Mounjaro, Zepbound, Kisunla |
| Merck Sharp & Dohme LLC | $158.37 | 2022-2024 | Zerbaxa, Dificid, Belsomra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $88.92 | 2023-2024 | Xifaxan |
| Glaxosmithkline, LLC. | $86.94 | 2023-2025 | Trelegy Ellipta, Nucala |
| Mylan Specialty L.P. | $76.86 | 2022-2024 | Yupelri |
| Electromed, INC. | $74.69 | 2022-2023 | Smartvest |
| Novartis Pharmaceuticals Corporation | $73.52 | 2022-2025 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $71.16 | 2023 | Acthar |
| Amgen INC. | $60.16 | 2023-2024 | Prolia, Evenity, Tavneos |
| Ardelyx, INC. | $50.87 | 2024 | Ibsrela |
| Baxter Healthcare | $44.71 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Grifols USA, LLC | $41.91 | 2022-2024 | Prolastin-C Liquid |
| Alnylam Pharmaceuticals INC. | $35.83 | 2023-2024 | Amvuttra |
| Genentech USA, INC. | $35.70 | 2023-2024 | Xolair |
| Teva Pharmaceuticals USA, INC. | $35.01 | 2023-2025 | Austedo Xr, Austedo Xr |
| Fresenius Kabi USA, LLC | $34.94 | 2024-2025 | Stimufend |
| Inogen, INC. | $34.88 | 2022-2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Novo Nordisk INC | $33.67 | 2023-2024 | Wegovy |
| Exact Sciences Corporation | $31.21 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $29.23 | 2023 | Glassia |
| Axsome Therapeutics, INC. | $26.64 | 2023 | Sunosi |
| Tactile Systems Technology INC | $21.84 | 2024 | Entre Plus, Flexitouch Plus |
| Ferring Pharmaceuticals INC. | $21.05 | 2023 | Rebyota |
| Viatris Specialty LLC | $20.94 | 2025 | Yupelri |
| Organon LLC | $20.06 | 2023 | Ontruzant |
| Agios Pharmaceuticals, INC. | $19.61 | 2025 | Pyrukynd |
| Janssen Pharmaceuticals, INC | $16.57 | 2022 | |
| Idorsia Pharmaceuticals US INC | $16.22 | 2023 | Quviviq |
| Sumitomo Pharma America, INC. | $15.80 | 2024 | Gemtesa |
| Ani Pharmaceuticals, INC. | $15.61 | 2025 | Purified Cortrophin Gel |
| Verona Pharma, INC. | $14.33 | 2025 | Ohtuvayre |
| Shield Therapeutics INC | $13.26 | 2023 | Accrufer |
| Covis Pharma Gmbh | $12.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Meyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.